Macau
-
Warminster Biopharma Firm Ends $285M Licensing Deal with Chinese Company
Warminster-based Arbutus Biopharma has ended a 4-year licensing deal worth up to $285 million with Qilu Pharmaceuticals, a Chinese drugmaker, writes John George for the…
-
Warrington’s Windtree Therapeutics Partners with China-Based Lee’s Pharma for Heart Disease Drug Expansion in Asia
Warrington-based biopharmaceutical firm Windtree Therapeutics is entering a multimillion-dollar licensing deal with a Chinese drug company for its three new cardiovascular disease drug candidates, writes…
Founding Partners
Advertisement
Affiliate Partners
